Related references
Note: Only part of the references are listed.Realizing drug repositioning by adapting a recommendation system to handle the process
Makbule Guclin Ozsoy et al.
BMC BIOINFORMATICS (2018)
Anaplastic thyroid carcinoma: review of treatment protocols
Vera Tiedje et al.
ENDOCRINE-RELATED CANCER (2018)
Lipid lowering agents of natural origin: An account of some promising chemotypes
Suriya P. Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer
Naiyarat Prasongsook et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Combined Treatment with Troglitazone and Lovastatin Inhibited Epidermal Growth Factor-Induced Migration through the Downregulation of Cysteine-Rich Protein 61 in Human Anaplastic Thyroid Cancer Cells (vol 3, e0118674, 2015)
Li-Han Chin et al.
PLOS ONE (2017)
Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells
Li-Han Chin et al.
MOLECULAR CARCINOGENESIS (2016)
Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?
Ange Wang et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
The interplay between cell signalling and the mevalonate pathway in cancer
Peter J. Mullen et al.
NATURE REVIEWS CANCER (2016)
Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Mrinal Gupta et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2015)
Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling
Amreen Mughal et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Chemotherapy and Chemoprevention by Thiazolidinediones
Eleonore Froehlich et al.
BIOMED RESEARCH INTERNATIONAL (2015)
PPAR gamma gene - A review
C. Janani et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2015)
Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience
A. Mohebati et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Super-radical surgery for anaplastic thyroid carcinoma: A large cohort study using the Anaplastic Thyroid Carcinoma Research Consortium of Japan database
Iwao Sugitani et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Bogna Grygiel-Gorniak
NUTRITION JOURNAL (2014)
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists
Kenneth K. W. To et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma
Juanita J. Evans et al.
CANCER BIOLOGY & THERAPY (2012)
PPAR gamma, bioactive lipids, and cancer progression
Gregory T. Robbins et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway
Wen-Bin Zhong et al.
BIOCHEMICAL PHARMACOLOGY (2011)
In vivo evidence of duality effects for lovastatin in a nude mouse cancer model
Chih-Yuan Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Breast cancer growth prevention by statins
Michael J. Campbell et al.
CANCER RESEARCH (2006)
Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid
Brian R. Untch et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2006)
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
CJ Yao et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes
KK Ray et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling
WB Zhong et al.
ENDOCRINE-RELATED CANCER (2005)
Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2
S Wakino et al.
CIRCULATION RESEARCH (2004)
Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers
M Onda et al.
JOURNAL OF HUMAN GENETICS (2004)
Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis
WB Zhong et al.
ENDOCRINOLOGY (2003)
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells
CY Wang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
B McIver et al.
SURGERY (2001)
Share Paper
